文献速递肺外科

全肺切除术患者的生存未被肺癌分期系统完全捕捉

Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System.
PubMed 文献 · Ann Thorac Surg · 2017-11-01

该研究基于美国国家癌症数据库2004至2013年接受肺叶或全肺切除的I至III期非小细胞肺癌患者,排除术后90天内死亡者,采用倾向评分加权多变量Cox模型分析5年总生存。结果显示全肺切除(尤其右全肺)的调整生存劣于肺叶切除,提示现行分期未完全反映全肺切除的生存风险。

要点

  • I、II期右全肺切除5年OS低于左全肺,左全肺低于肺叶切除。
  • III期右全肺切除死亡风险高于肺叶切除(HR 1.23),左全肺与肺叶切除相似。
  • 全肺切除的生存风险未被分期系统完全捕捉,需细化生存评估。

核心结论

  • 需要全肺切除的肺癌患者存在现行分期系统未完全捕捉的5年死亡风险。
  • 细化全肺切除患者的生存估计可能改善共享决策。

研究设计与样本

  • 回顾性队列研究,查询美国国家癌症数据库2004至2013年数据。
  • 纳入初治、接受肺叶或全肺切除的I至III期非小细胞肺癌患者,排除术后90天内死亡者,共79,953例(肺叶切除75,708例,全肺切除4,245例)。
  • 采用三向倾向评分加权多变量Cox模型并构建调整5年总生存曲线。

主要发现

  • I期调整5年OS:右全肺55%、左全肺58%、肺叶切除67%。
  • II期调整5年OS:右全肺37%、左全肺44%、肺叶切除48%。
  • III期调整5年OS:右全肺33%、左全肺39%、肺叶切除40%,左全肺与肺叶切除相似。
  • 双稳健Cox模型显示I、II期死亡风险右全肺>左全肺>肺叶切除;III期右全肺死亡风险高于肺叶切除(HR 1.23,95%CI 1.17-1.28,p<0.001),左全肺与肺叶切除相似(HR 1.02,95%CI 0.97-1.06,p=0.47)。

临床怎么用

  • 与需全肺切除的肺癌患者沟通时,应告知其生存可能劣于同分期肺叶切除患者。
  • 对I、II期及III期右全肺切除患者,可参考细化生存估计辅助治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer patients rely on survival estimates to weigh risks and benefits of treatment. However, pneumonectomy-requiring lung cancer may have inherent oncologic or physiologic survival implications not captured by the current stage classification. Stage-specific survival was evaluated to refine survival expectations for patients with pneumonectomy-requiring disease. METHODS: The National Cancer Database was queried for treatment-naive patients who underwent lobectomy or pneumonectomy for stage I to III non-small cell lung cancer between 2004 and 2013. Patients who died within 90 days after resection were excluded. Three-way propensity score weighted multivariable Cox models were built and incorporated into adjusted 5-year overall survival (OS) curves. RESULTS: A total of 79,953 patients met inclusion criteria: 75,708 lobectomies (95%) and 4,245 pneumonectomies (5%). Stage I and II patients undergoing right pneumonectomy had worse adjusted 5-year OS than patients undergoing left pneumonectomy, which was worse than lobectomy (stage I: 55%, 58%, 67%; stage II: 37%, 44%, 48%; indicating right pneumonectomy, left pneumonectomy, lobectomy). Stage III right pneumonectomy patients had worse adjusted 5-year OS; however, left pneumonectomy and lobectomy patients were similar (33%, 39%, 40%). A doubly robust Cox model identified a similar pattern for mortality risk for stage I and II (right pneumonectomy > left > lobectomy); however, stage III right pneumonectomy patients had higher mortality risk than lobectomy patients (hazard ratio [HR] 1.23, 95% confidence interval [CI]: 1.17 to 1.28, p < 0.001), whereas left pneumonectomy was similar to lobectomy (HR 1.02, 95% CI: 0.97 to 1.06, p = 0.47). CONCLUSIONS: Pneumonectomy-requiring lung cancer embodies a 5-year mortality risk not completely captured by the lung cancer staging system. Refined survival estimates for pneumonectomy patients may enhance shared decision making in this population.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Dhanasopon AP, Salazar MC, Hoag JR, et al. Fate of Pneumonectomy Patients Variably Captured by Non-Small Cell Lung Cancer Staging System. Ann Thorac Surg. 2017. PMID: 29074151. doi:10.1016/j.athoracsur.2017.06.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。